In September 2024, AMCP and Impact Education, LLC, held a virtual Market Insights summit with chief medical and pharmacy officers and other senior health care executives to discuss the management of retinal diseases in patients with diabetes.
Idiopathic hypersomnia (IH) is a chronic, neurologic disorder with a primary symptom of excessive daytime sleepiness
Findings published in JMCP for a 3-phase AMCP Market Insights program on Food Allergies that included a national survey of managed care professionals, in-depth interviews with managed care experts, and a moderated virtual roundtable discussion including clinical and managed care experts.
Key insights from the discussion related to supporting patient needs in MS, advancing understanding of MS, emerging treatments in MS, using real-world evidence in MS coverage decision-making, and addressing continued challenges in MS. Suggested payer best practices in MS also emerged from the discussion.
Retinal diseases in patients with diabetes pose signi cant challenges for health care systems. With a high treatment burden and advances in durable therapies, managed care organizations can optimize patient care by addressing coverage barriers that impact timely treatment with anti-VEGF therapies. This roadmap outlines essential points to better retinal disease management and improve treatment for populations of patients with diabetes at high risk for blindness.
View our webinar on Managed Care Approaches to Address Unmet Patient Needs in Multiple Sclerosis (MS), a disease affecting nearly 1 million people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
View our Market Insights webinar that features an enlightening exploration of the intersection between mental health and rare diseases.
The AMCP Poster Abstract Program provides a forum for authors to share their research with the managed care pharmacy community.
People with rare diseases often have mental health challenges related to their health care. These vary by disease, but there are common issues that make it difficult for individuals and their families, including delays in getting diagnosed, not knowing what will happen in the future, having limited treatments, and facing financial difficulties.
View our Market Insights webinar that features a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable.
Panel of experts discussing targeted therapies to deliver improved patient outcomes in oncology.
Exploring opportunities to improve the quality of life for those with Amyotrophic Lateral Sclerosis (ALS)
